Back to Search
Start Over
Naru-3 inhibits inflammation, synovial hyperplasia, and neovascularization in collagen-induced arthritis in rats.
- Source :
-
Journal of Ethnopharmacology . Jul2023, Vol. 311, pN.PAG-N.PAG. 1p. - Publication Year :
- 2023
-
Abstract
- Naru-3 is a prescribed formulation based on the theory of Mongolian medicine for the treatment of rheumatoid arthritis (RA). Naru-3 consists of three medicinal agents: Aconitum kusnezoffii Reichb (caowu), Terminalia chebula Retz (hezi), and Piper longum L (biba). These medicinal agents are widely distributed in the Mongolian area of China and have been used to treat rheumatism for centuries. Mongolian medicine Naru-3 is commonly prescribed to treat RA, but its mechanism of action is unknown. A rat collagen-induced arthritis (CIA) model was established to investigate the mechanism of Naru-3. Rats were treated with Naru-3, Etanercept (ETN), and sodium carboxymethylcellulose (CMC) for four weeks. After treatment was terminated, paw thickness, ankle diameter, and arthritis index (AI) were scored. Synovial hyperplasia was evaluated using hematoxylin and eosin (H&E) staining and two-dimensional ultrasonography. Synovitis and neovascularization were assayed using power Doppler imaging (PDI) and contrast-enhanced ultrasonography (CEUS). Levels of vascular endothelial growth factor (VEGF), interleukin (IL)-1, and CD31 in the serum or synovium were detected using ELISA and immunohistochemistry analyses. Naru-3 and ETN alleviated the symptoms of CIA as evidenced by diminished paw thickness, ankle diameter, and AI scores. Mechanistically, Naru-3 inhibited synovial hyperplasia, synovitis, and neovascularization by diminishing systemic and local inflammation, as indicated by the relative expression of CD31, VEGF and IL-1 in the serumor synovium. After four weeks of treatment, no significant neovascularization was observed in the Naru-3 group, but neovascularization and synovitis occurred in the ETN group, as demonstrated by H&E staining, PDI, and CEUS examination. Naru-3 inhibited inflammation, synovial hyperplasia, and neovascularization and alleviates RA in our CIA rat model. No symptom recurrence was observed four weeks after drug treatment. [Display omitted] • This paper illustrats the mechanisms of action of Naru-3 in the treatment of RA through inhibition of synovial neovascularization. • No symptom recurrence is observed four weeks after Naru-3 treatment. • CEUS for evaluating synovial neovascularization provides reference for clinical visualization evaluation of drug efficacy. [ABSTRACT FROM AUTHOR]
- Subjects :
- *DRUG therapy for arthritis
*COLLAGEN
*DRUG efficacy
*SYNOVIAL membranes
*ANTI-inflammatory agents
*INFLAMMATION
*ANIMAL experimentation
*IMMUNOHISTOCHEMISTRY
*HYPERPLASIA
*INTERLEUKIN-1
*TRADITIONAL medicine
*TREATMENT effectiveness
*RATS
*PATHOLOGIC neovascularization
*DOPPLER ultrasonography
*ENZYME-linked immunosorbent assay
*VASCULAR endothelial growth factors
*ETANERCEPT
*PHARMACODYNAMICS
Subjects
Details
- Language :
- English
- ISSN :
- 03788741
- Volume :
- 311
- Database :
- Academic Search Index
- Journal :
- Journal of Ethnopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 163308662
- Full Text :
- https://doi.org/10.1016/j.jep.2023.116350